Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.

Shekhar TM, Burvenich IJG, Harris MA, Rigopoulos A, Zanker D, Spurling A, Parker BS, Walkley CR, Scott AM, Hawkins CJ.

BMC Cancer. 2019 Sep 14;19(1):924. doi: 10.1186/s12885-019-6103-5.

2.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

3.

Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides.

Smedley CJ, Zheng Q, Gao B, Li S, Molino A, Duivenvoorden HM, Parker BS, Wilson DJD, Sharpless KB, Moses JE.

Angew Chem Int Ed Engl. 2019 Mar 26;58(14):4552-4556. doi: 10.1002/anie.201813761. Epub 2019 Feb 27.

PMID:
30740848
4.

Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers.

Duivenvoorden HM, Spurling A, O'Toole SA, Parker BS.

PLoS One. 2018 Jul 25;13(7):e0201370. doi: 10.1371/journal.pone.0201370. eCollection 2018.

5.

Sustainable Syntheses of (-)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding Site.

Smedley CJ, Stanley PA, Qazzaz ME, Prota AE, Olieric N, Collins H, Eastman H, Barrow AS, Lim KH, Kam TS, Smith BJ, Duivenvoorden HM, Parker BS, Bradshaw TD, Steinmetz MO, Moses JE.

Sci Rep. 2018 Jul 13;8(1):10617. doi: 10.1038/s41598-018-28880-2.

6.

Tumor inherent interferons: Impact on immune reactivity and immunotherapy.

Brockwell NK, Parker BS.

Cytokine. 2019 Jun;118:42-47. doi: 10.1016/j.cyto.2018.04.006. Epub 2018 Apr 19. Review.

PMID:
29681426
7.

Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis.

Owen KL, Parker BS.

Mol Immunol. 2019 Jun;110:57-68. doi: 10.1016/j.molimm.2017.11.023. Epub 2017 Nov 27. Review.

PMID:
29191489
8.

Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential.

Gangoda L, Liem M, Ang CS, Keerthikumar S, Adda CG, Parker BS, Mathivanan S.

Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201600370.

PMID:
29115712
9.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
10.

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.

Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.

11.

Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.

Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG, Cutts SM.

ACS Med Chem Lett. 2017 Apr 24;8(5):538-542. doi: 10.1021/acsmedchemlett.7b00090. eCollection 2017 May 11.

12.

Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.

Touati N, Tryfonidis K, Caramia F, Bonnefoi H, Cameron D, Slaets L, Parker BS, Loi S.

Eur J Cancer. 2017 Feb;72:95-102. doi: 10.1016/j.ejca.2016.11.015. Epub 2016 Dec 24.

PMID:
28027521
13.

Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.

Samy KP, Anderson DJ, Lo DJ, Mulvihill MS, Song M, Farris AB, Parker BS, MacDonald AL, Lu C, Springer TA, Kachlany SC, Reimann KA, How T, Leopardi FV, Franke KS, Williams KD, Collins BH, Kirk AD.

Am J Transplant. 2017 May;17(5):1193-1203. doi: 10.1111/ajt.14141. Epub 2017 Jan 27.

14.

The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes.

Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, Lobb RJ, Castillo V, Wong KN, Ellis S, Parker BS, Möller A.

Cancer Res. 2016 Dec 1;76(23):6816-6827. Epub 2016 Oct 19.

15.

Legumain is activated in macrophages during pancreatitis.

Edgington-Mitchell LE, Wartmann T, Fleming AK, Gocheva V, van der Linden WA, Withana NP, Verdoes M, Aurelio L, Edgington-Mitchell D, Lieu T, Parker BS, Graham B, Reinheckel T, Furness JB, Joyce JA, Storz P, Halangk W, Bogyo M, Bunnett NW.

Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G548-60. doi: 10.1152/ajpgi.00047.2016. Epub 2016 Aug 11.

16.

Antitumour actions of interferons: implications for cancer therapy.

Parker BS, Rautela J, Hertzog PJ.

Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14. Review.

PMID:
26911188
17.

Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.

Edgington-Mitchell LE, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M, Parker BS.

Oncotarget. 2015 Sep 29;6(29):27008-22. doi: 10.18632/oncotarget.4714.

18.

Loss of Siah2 does not impact angiogenic potential of murine endothelial cells.

Wong CS, Chen A, Liu MC, Parker BS, Möller A.

Microvasc Res. 2015 Nov;102:38-45. doi: 10.1016/j.mvr.2015.08.003. Epub 2015 Aug 11.

PMID:
26275748
19.

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.

Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A, Parker BS.

Cancer Immunol Res. 2015 Nov;3(11):1207-17. doi: 10.1158/2326-6066.CIR-15-0065. Epub 2015 Jul 21.

20.

Bone specific immunity and its impact on metastasis.

Baschuk N, Rautela J, Parker BS.

Bonekey Rep. 2015 Apr 15;4:665. doi: 10.1038/bonekey.2015.32. eCollection 2015. Review.

21.

Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.

Gangoda L, Keerthikumar S, Fonseka P, Edgington LE, Ang CS, Ozcitti C, Bogyo M, Parker BS, Mathivanan S.

Oncotarget. 2015 May 10;6(13):11175-90.

22.

Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?

Croucher PI, Parker BS, Corcoran N, Rogers MJ.

Eur Urol. 2015 Jul;68(1):51-2. doi: 10.1016/j.eururo.2014.10.041. Epub 2014 Nov 11. No abstract available.

PMID:
25466938
23.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL.

Cancer Res. 2014 Sep 15;74(18):5091-102. doi: 10.1158/0008-5472.CAN-13-3171.

24.

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

Slaney CY, Rautela J, Parker BS.

Cancer Res. 2013 Oct 1;73(19):5852-7. doi: 10.1158/0008-5472.CAN-13-1642. Epub 2013 Sep 23. Review.

25.

Hyperendemic malaria transmission in areas of occupation-related travel in the Peruvian Amazon.

Parker BS, Paredes Olortegui M, Peñataro Yori P, Escobedo K, Florin D, Rengifo Pinedo S, Cardenas Greffa R, Capcha Vega L, Rodriguez Ferrucci H, Pan WK, Banda Chavez C, Vinetz JM, Kosek M.

Malar J. 2013 May 31;12:178. doi: 10.1186/1475-2875-12-178.

26.

Evaluating sleep and cognition in HIV.

Gamaldo CE, Gamaldo A, Creighton J, Salas RE, Selnes OA, David PM, Mbeo G, Parker BS, Brown A, McArthur JC, Smith MT.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):609-16. doi: 10.1097/QAI.0b013e31829d63ab.

27.

Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Woodward OM, Tukaye DN, Cui J, Greenwell P, Constantoulakis LM, Parker BS, Rao A, Köttgen M, Maloney PC, Guggino WB.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5223-8. doi: 10.1073/pnas.1214530110. Epub 2013 Mar 14.

28.

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche.

Sceneay J, Parker BS, Smyth MJ, Möller A.

Oncoimmunology. 2013 Jan 1;2(1):e22355.

29.

The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone.

Slaney CY, Möller A, Hertzog PJ, Parker BS.

Oncoimmunology. 2013 Jan 1;2(1):e22339.

30.

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS.

Nat Med. 2012 Aug;18(8):1224-31. doi: 10.1038/nm.2830. Epub 2012 Jul 22.

PMID:
22820642
31.

Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche.

Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ, Möller A.

Cancer Res. 2012 Aug 15;72(16):3906-11. doi: 10.1158/0008-5472.CAN-11-3873. Epub 2012 Jul 2.

32.

Strategies for the discovery and development of therapies for metastatic breast cancer.

Eckhardt BL, Francis PA, Parker BS, Anderson RL.

Nat Rev Drug Discov. 2012 Jun 1;11(6):479-97. doi: 10.1038/nrd2372. Review.

PMID:
22653217
33.

Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy.

Wong CS, Sceneay J, House CM, Halse HM, Liu MC, George J, Hunnam TC, Parker BS, Haviv I, Ronai Z, Cullinane C, Bowtell DD, Möller A.

Cancer Res. 2012 Apr 1;72(7):1694-704. doi: 10.1158/0008-5472.CAN-11-3310. Epub 2012 Feb 21.

34.

Cathepsin B inhibition limits bone metastasis in breast cancer.

Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS.

Cancer Res. 2012 Mar 1;72(5):1199-209. doi: 10.1158/0008-5472.CAN-11-2759. Epub 2012 Jan 19.

35.

The continued lived experience of the unexpected death of a child.

Parker BS, Dunn KS.

Omega (Westport). 2011;63(3):221-33.

PMID:
21928597
36.

Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis.

Kusuma N, Denoyer D, Eble JA, Redvers RP, Parker BS, Pelzer R, Anderson RL, Pouliot N.

Int J Cancer. 2012 Feb 1;130(3):555-66. doi: 10.1002/ijc.26018. Epub 2011 May 5.

37.

Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.

Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, Slavin JL, Möller A, Steel R, Pouliot N, Eckhardt B, Henderson MA, Anderson RL.

J Pathol. 2008 Feb;214(3):337-46.

PMID:
17985332
38.

Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix.

Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL.

Mol Cancer Res. 2005 Jan;3(1):1-13.

39.

Alterations in vascular gene expression in invasive breast carcinoma.

Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL.

Cancer Res. 2004 Nov 1;64(21):7857-66. Erratum in: Cancer Res. 2004 Dec 1;64(23):8794.

40.

Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

Parker BS, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Oncol Res. 2004;14(6):279-90.

PMID:
15206490
41.

A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR.

J Biol Chem. 2004 Apr 30;279(18):18814-23. Epub 2004 Feb 12.

42.

Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal.

Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC.

Mol Psychiatry. 2004 Apr;9(4):358-70.

PMID:
14745455
43.

Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S.

Cancer Biol Ther. 2003 May-Jun;2(3):259-63.

PMID:
12878861
44.

Structural requirements for the formation of anthracycline-DNA adducts.

Cutts SM, Parker BS, Swift LP, Kimura KI, Phillips DR.

Anticancer Drug Des. 2000 Oct;15(5):373-86.

PMID:
11354313
45.

Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides.

Parker BS, Cutts SM, Phillips DR.

J Biol Chem. 2001 May 11;276(19):15953-60. Epub 2001 Feb 13.

46.

Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Parker BS, Cutts SM, Cullinane C, Phillips DR.

Nucleic Acids Res. 2000 Feb 15;28(4):982-90.

47.

Formation of DNA adducts by formaldehyde-activated mitoxantrone.

Parker BS, Cullinane C, Phillips DR.

Nucleic Acids Res. 1999 Jul 15;27(14):2918-23.

Supplemental Content

Loading ...
Support Center